135 related articles for article (PubMed ID: 9690943)
1. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application.
Kirchner GI; Franzke A; Buer J; Beil W; Probst-Kepper M; Wittke F; Overmann K; Lassmann S; Hoffmann R; Kirchner H; Ganser A; Atzpodien J
Br J Clin Pharmacol; 1998 Jul; 46(1):5-10. PubMed ID: 9690943
[TBL] [Abstract][Full Text] [Related]
2. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous recombinant interleukin 2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma.
Whitehead RP; Ward D; Hemingway L; Hemstreet GP; Bradley E; Konrad M
Cancer Res; 1990 Oct; 50(20):6708-15. PubMed ID: 2208137
[TBL] [Abstract][Full Text] [Related]
5. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
Yang JC; Rosenberg SA
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
[TBL] [Abstract][Full Text] [Related]
7. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of very low doses of immunotherapy in advanced renal cell cancer.
Buzio C; De Palma G; Passalacqua R; Potenzoni D; Ferrozzi F; Cattabiani MA; Manenti L; Borghetti A
Br J Cancer; 1997; 76(4):541-4. PubMed ID: 9275034
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
Lopez Hänninen E; Kirchner H; Atzpodien J
J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
[TBL] [Abstract][Full Text] [Related]
10. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
11. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of recombinant human interleukin-11 (rhIL-11) in healthy male subjects.
Aoyama K; Uchida T; Takanuki F; Usui T; Watanabe T; Higuchi S; Toyoki T; Mizoguchi H
Br J Clin Pharmacol; 1997 Jun; 43(6):571-8. PubMed ID: 9205816
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of repeated i.v. bolus administration of high doses of r-met-Hu interleukin-2 in advanced cancer patients.
Sculier JP; Body JJ; Donnadieu N; Nejai S; Glibert F; Raymakers N; Paesmans M
Cancer Chemother Pharmacol; 1990; 26(5):355-8. PubMed ID: 2208578
[TBL] [Abstract][Full Text] [Related]
14. [Clinical experience with the treatment of metastatic renal cell carcinoma with subcutaneous interleukin-2r (IL-2r) and interferon Alpha-2b (IFN Alfa-2b)].
Olivier C; Carballido J; Lao AH; Gimeno A; Martín C; Renjifo D; Ondina LM; Manzano L; Alvarez-Mon M
Actas Urol Esp; 1995 Jan; 19(1):16-26. PubMed ID: 7717154
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.
Angevin E; Valteau-Couanet D; Farace F; Dietrich PY; Lecesne A; Triebel F; Escudier B
J Immunother Emphasis Tumor Immunol; 1995 Oct; 18(3):188-95. PubMed ID: 8770775
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
Smith WB; Dowell JA; Pratt RD
Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of teceleukin (recombinant human interleukin-2) after intravenous or subcutaneous administration to patients with cancer.
Gustavson LE; Nadeau RW; Oldfield NF
J Biol Response Mod; 1989 Aug; 8(4):440-9. PubMed ID: 2787839
[TBL] [Abstract][Full Text] [Related]
18. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2.
Buter J; Sleijfer DT; van der Graaf WT; de Vries EG; Willemse PH; Mulder NH
Semin Oncol; 1993 Dec; 20(6 Suppl 9):16-21. PubMed ID: 8284687
[No Abstract] [Full Text] [Related]
19. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of advanced renal cell carcinoma with subcutaneous administration of interleukin 2 and interferon-alpha].
Hofmockel G; Theiss M; Bussen D; Wirth MP; Frohmüller HG
Urologe A; 1994 Sep; 33(5):434-9. PubMed ID: 7974933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
